Confidently Backed by the Extensive Experimental and AI Expertise of Two Industry Leaders: Charles River + Valo Health
Logica® is a transformative solution that redefines the drug discovery journey. We’re not just an AI-enabled point solution or add-on; we’re your partner in crafting small molecule solutions tailored to your specifications.
Our integrated, AI-driven drug discovery process sets us apart from traditional outsourcing, ensuring outcomes that we align collaboratively to your drug discovery objectives. Explore our three powerful solutions that are redefining the state of the art in AI drug discovery solutions: Logica-A (in vitro biology), Logica-B (pharmacokinetics), and Logica-C (efficacy).
Engage with any single phase or combination of phases. Choose the path that meets your specific program needs.
Logica-A: In Vitro Biology
The journey to understanding your compounds begins with Logica-A. Our expertise-driven approach to the identification, characterization, and initial optimization of hit matter includes a comprehensive range of AI-driven drug discovery processes:
Comprehensive Hit Identification Capabilities
- Leverage >30 billion compound virtual library, >1 million member high-throughput screening (HTS library), and >13-billion-member DNA-encoded compound library (DEL) data
- Harness expert knowledge and data science with large, wide-ranging datasets to systematically sort and characterize compound activity and quality
Targeted Compound Characterization
- Pair AI-/ML-based models with in vitro biology assays to characterize your most promising compounds
- Conduct comprehensive target assays, selectivity panels, and initial characterization to identify an advanceable lead series
Logica-B: Pharmacokinetics & Pharmacodynamics
Knowing how your compounds behave and respond in biological systems is paramount for successful drug development. Logica-B provides the comprehensive pharmacokinetics (PK), pharmacodynamics (PD), and biological de-risking needed to confidently guide your program forward.
PK Analysis and Optimization
- Comprehensive ADME profiling to understand compound behavior
- In vivo pharmacokinetics assessment across relevant species
- Bioavailability and distribution analysis
- Metabolic pathway characterization
- Translational PK/PD support during lead optimization and into candidate selection
Data-Driven Decision-Making
- Integration of PK/PD datasets with predictive modeling
- Optimization recommendations for improved drug-like properties
- Risk assessment for advancement decisions
Logica-C: Efficacy and Therapeutic Window
With Logica-C, we focus on demonstrating efficacy and safety, establishing appropriate therapeutic windows for your candidate molecules.
Efficacy and Safety Assessment
- Conduct PD studies to understand target engagement in vivo and inform doses for efficacy study
- Establish therapeutic window through integrated efficacy models, PK/PD, and non-GLP rodent toxicology
- Provide clear go/no-go recommendations based on therapeutic index analysis
Building on a Legacy of Success
With over 100 candidates provided to clients through Charles River, our expertise spans numerous therapeutic areas and target classes.
Therapeutic Areas
CNS
Oncology
Fibrosis
Respiratory
Anti-infective
And others
Target Classes
Kinases
Phenotypic targets
Ion channels
Proteases
Enzymes
RNA targets
Transcription factors
Membrane receptors
GPCRs
And others
Accelerate and Ensure Your AI-Driven Drug Discovery Journey With Logica’s Distinctive Deliverables
To help ensure your success, we aim to deliver on three key outcomes: Certainty, Quality, Advanceability.
CERTAINTY
Obtain clear characterization of your compound’s in vitro biology profile
QUALITY
Comprehensive assessment using validated assays and proven methodologies
ADVANCEABILITY
Clear data package supporting informed advancement decisions
CERTAINTY
PK/PD and exposure–response modeling to predict dose, schedule, and therapeutic window
QUALITY
Validated bioanalytical methods and standardized ADME/PK workflows for reproducible, audit-ready data
ADVANCEABILITY
Data-driven recommendations for optimization and advancement
CERTAINTY
Demonstrate clear in vivo target engagement (or orthogonal) signal
QUALITY
De-risked molecules which modulate the target in vivo
ADVANCEABILITY
Clear therapeutic index data supporting advancement to formal development